Goodwin Procter LLP advised Valo Health on the deal, while Latham & Watkins LLP represented Khosla Ventures Acquisition Co. Valo Health announced its definitive merger agreement with...
Valo Health’s $2.8 Billion Merger with Khosla Ventures Acquisition Co.
Ginkgo Bioworks’ $15 Billion Merger with Soaring Eagle Acquisition Corp.
Latham & Watkins LLP and Wachtell, Lipton, Rosen & Katz represented Ginkgo Bioworks, while White & Case LLP advised Soaring Eagle Acquisition Corp. in the transaction....
Rain Therapeutics’ $125 Million Initial Public Offering
Latham & Watkins LLP represented the underwriters in the offering. Rain Therapeutics Inc. (Rain), a clinical-stage company developing precision oncology therapeutics, executed its initial public offering...
Treace Medical Concepts’ $106.3 Million Initial Public Offering
Latham & Watkins LLP represented Treace Medical Concepts, Inc. in the offering. Treace Medical Concepts, Inc. (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a...
Biomea’s $153 Million Initial Public Offering
Latham & Watkins LLP represented Biomea Fusion, Inc. in the transaction. Biomea Fusion, Inc. (Nasdaq: BMEA) closed its initial public offering of 9 million shares of its...
Reneo Pharmaceuticals’ $93.8 Million Initial Public Offering
Latham & Watkins LLP represents the underwriters in the offering while Wilson Sonsini Goodrich & Rosati advised Reneo Pharmaceuticals, Inc. Reneo Pharmaceuticals, Inc. has announced the pricing...
Design Therapeutics’s $276 Million Initial Public Offering
Latham & Watkins LLP represented the underwriters in the offering while Wilson Sonsini Goodrich & Rosati advised Design Therapeutics, Inc. Design Therapeutics, Inc. executed its initial public...
Connect Biopharma’s $219.9 Million Initial Public Offering
Latham & Watkins LLP and Maples and Calder represented Connect Biopharma in the transaction. Global Law Office and Davis Polk advised joint book-running managers. Connect Biopharma...
Chardan Healthcare Acquisition 2 Corp.’s Merger with Renovacor
Latham & Watkins represented Chardan Healthcare Acquisition 2 Corp. in the transaction. Renovacor, Inc. (Renovacor), an early-stage biotechnology company developing AAV-based gene therapies for devastating cardiovascular...
Longboard Pharmaceuticals’ $80.0 Million Initial Public Offering
Latham & Watkins LLP represented the underwriters in the offering. Longboard Pharmaceuticals, Inc. closed its initial public offering of 5 million shares of its common stock at...
Boston Scientific’s $1.07 Billion Acquisition of Lumenis Surgical Business
Ropes & Gray represented an affiliate of Baring Private Equity Asia in the transaction, while Yigal Arnon & Co. and Latham & Watkins represented Boston Scientific,...
Owlet Baby Care’s $1.39 Billion Merger with Sandbridge Acquisition Corporation
Latham & Watkins LLP advised Owlet Baby Care, while Ropes & Gray LLP advised Sandbridge on the deal. Owlet Baby Care Inc. and Sandbridge Acquisition Corporation...